Anti-Inflammatory Effect of Specialized Proresolving Lipid Mediators on Mesenchymal Stem Cells: An In Vitro Study

• Published in: Cells (Basel, Switzerland) Vol. 12; no. 1; p. 122
• Main Authors: AlZahrani, Shahd, Shinwari, Zakia, Gaafar, Ameera, Alaiya, Ayodele, Al-Kahtani, Ahmed
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28.12.2022; MDPI
• Subjects: Analysis; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Anti-inflammatory drugs; Apoptosis; Biosynthesis; Bone marrow; Cell growth; Cell migration; Cell proliferation; Composition; Cytokines; Diagnosis; Dosage and administration; Drug therapy; Eicosanoids; Eicosapentaenoic acid; Experiments; hBMMSCs; Health aspects; Humans; Infections; Inflammation; Inflammation - metabolism; Interleukin 4; Lipid metabolism; Lipids; Lipopolysaccharides; Maresin1; Mesenchymal stem cells; Mesenchymal Stem Cells - metabolism; Microbiota (Symbiotic organisms); Neutrophils; Patient outcomes; Periodontitis; Protein expression; Regeneration; Resolvin E1; SPMs; Stem cells; Tissue engineering; Transforming growth factor-b1; Tumor necrosis factor-α; Western blotting; γ-Interferon; Saudi Arabia; St Louis Missouri; Los Angeles California; United States > US; hBMMSCs; stem cells; Maresin1; SPMs; inflammation; Resolvin E1; LPS
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells12010122

An interconnection between tissue inflammation and regeneration has been established through the regulation of defense and repair mechanisms within diseased dental tissue triggered by the release of immune-resolvent mediators. To better our understanding of the role of specific pro-resolving mediators (SPMs) in inflamed human bone marrow-derived mesenchymal stem cells (hBMMSCs), we studied the effects of Resolvin E1 (RvE1) and Maresin 1 (MaR1) in lipopoly-saccharide (LPS) stimulated hBMMSCs. The hBMMSCs were divided into five different groups, each of which was treated with or without SPMs. Group-1: negative control (no LPS stimulation), Group-2: positive control (LPS-stimulated), Group-3: RvE1 100 nM + 1 μg/mL LPS, Group-4: MaR1 100 nM + 1 µg/mL LPS, and Group-5: RvE1 100 nM + MaR1100 nM + 1 μg/mL LPS. Cell proliferation, apoptosis, migration, colony formation, Western blotting, cytokine array, and LC/MS analysis were all performed on each group to determine the impact of SPMs on inflammatory stem cells. According to our data, RvE1 plus MaR1 effectively reduced inflammation in hBMMSCs. In particular, IL-4, 1L-10, and TGF-β1 activation and downregulation of RANKL, TNF-α, and IFN-γ compared to groups receiving single SPM were shown to be significantly different (Group 3 and 4). In addition, the LC/MS analysis revealed the differentially regulated peptide's role in immunological pathways that define the cellular state against inflammation. Inflamed hBMMSCs treated with a combination of Resolvin E1 (RvE1) and Maresin 1 (MaR1) promoted the highest inflammatory resolution compared to the other groups; this finding suggests a potential new approach of treating bacterially induced dental infections.